$CRDF

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (6m)

—

Win rate (6m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 29m ago

$CRDFr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/SeniorVicePrez · 2h ago1 prior · awaiting results

Long CRDF

Settlement yesterday is just the beginning for CRDF

Cardiff Oncology settlement with NMS removes litigation overhang and advances onvansertib to Phase 3 for RAS-mutated colorectal cancer. Recent HC Wainwright upgrade to BUY with $9 PT, insider buying at ~$1.50, and preliminary data showing superiority over standard-of-care support significant upside from current levels.

Now $1.4129m ago

original post →

$CRDFr/pennystocksBullishbullish

u/SeniorVicePrez · 5d ago1 prior · awaiting results

“Large $1M insider purchase (Gary Pace) at cost average of roughly $1.50”

A big insider purchase got me into CRDF recently

Micro-cap biotech with Phase 3 catalyst potential for onvansertib in RAS-mutated metastatic colorectal cancer, a large underserved market. Recent positive Phase 2 readouts, FDA end-of-phase-2 meeting clearance, and a major insider $1M purchase at ~$1.50 cost basis suggest significant upside; pending patent dispute with NMS likely a negotiation tactic that resolution could unlock gains.

At post $1.21Now $1.41+16.5% since posted29m ago

1d0.0%

3d0.0%

1w—

1m—

3m—

6m—

1y—

original post →

End of results.